The Lupus Research Alliance (LRA) has awarded a $3-million grant to a multidisciplinary research group working to identify drivers of lupus nephritis, a serious complication of lupus characterized by kidney damage, in children with the autoimmune disease. Elena Hsieh, MD, an associate professor at the University of Colorado…
Younger age, greater disease activity, and a history of kidney involvement are significant predictors of severe disease flares among people with systemic lupus erythematosus (SLE), a study in Iran has found. The findings suggest that patients with these risk factors “may need closer monitoring and follow-up” to better manage…
A Phase 2 clinical trial assessing the safety and effectiveness of daxdilimab for systemic lupus erythematosus (SLE) didn’t show a statistically significant difference between the experimental therapy and a placebo regarding the proportion of patients who showed signs of reduced disease activity while lowering their daily corticosteroid dose. The…
Lupkynis (voclosporin) continues to be safe and to protect kidney function when taken for up to three years by patients with lupus nephritis, a kidney complication of lupus. That’s according to the full results from AURORA 2 (NCT03597464), a Phase 3 extension study that evaluated how safe…
Former NFL Super Bowl champ Willie Colon hosted a golf event earlier this week to raise funds for the Lupus Research Alliance (LRA) to aid in the fight against lupus. The event is expected to raise about $400,000 and the funds will support the Jean Davis Research Grant,…
The Lupus Research Alliance has named the winners of this year’s Awards to Promote Diversity in Lupus Research, all from underrepresented minority groups who are interested in studying lupus. Four researchers were selected to receive a Career Development Award, which provides up to $600,000 over four years to…
Kyverna Therapeutics is planning to launch a Phase 1/2 trial in Germany to test KYV-101, its investigational cell therapy for lupus nephritis, a lupus complication characterized by kidney damage. The study was approved by the Paul Ehrlich Institute (PEI), which is responsible for examining clinical trials of investigational…
A Phase 2b clinical trial of ESK-001, an oral treatment for systemic lupus erythematosus (SLE), has begun dosing patients, according to its developer Alumis. The trial, called LUMUS, is expected to enroll about 388 adults with moderately to severely active SLE who test positive for self-reactive antibodies (autoantibodies).
Trethera will use a $0.6 million Small Business Technology Transfer (STTR) grant to advance TRE-515, its lead candidate for systemic lupus erythematosus (SLE). The grant comes from the National Institute for Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), from which the company…
The first patient has been enrolled in a Phase 1 clinical trial testing KYV-101, Kyverna Therapeutics’ candidate cell therapy for refractory lupus nephritis, a serious lupus complication characterized by kidney damage and inflammation. The open-label trial, which follows FDA’s green light in November, is actively recruiting nine to…